Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Enfermedades Infecciosas | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 2
ClinicalTrials.gov
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Exploring the Safety, Tolerability, and Antiviral Effect of Substituting 600 mg Racivir for 3TC in HIV-Infected Subjects Who Have the M184V Mutation and Are Currently Failing on a HAART Regimen Containing Lamivudine
INTERVENTIONAL
Inicio: 1 de sept de 2004
ID: NCT00121979
Completado
Fase 3
ClinicalTrials.gov
Randomized, Double Blind, Placebo Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Argentine Healthy Population Aged Between 18 and 85 Years
INTERVENTIONAL
Inicio: 16 de sept de 2020
ID: NCT04560881
Completado
Fase 3
ClinicalTrials.gov
A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults
INTERVENTIONAL
Inicio: 28 de ene de 2021
ID: NCT04723394
Completado
Fase 3
ClinicalTrials.gov
Phase 2/3 Study to Evaluate Safety, Tolerability and Immunogenicity of a Recombinant Protein-based Vaccine Against SARS-CoV-2, in a Population of Adult Volunteers Previously Vaccinated Against SARS-CoV-2 Virus.
INTERVENTIONAL
Inicio: 6 de feb de 2023
ID: NCT05752201
Completado
Fase 2
ClinicalTrials.gov
A 48 Week, Phase II, Open-label, 2-cohort, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of GW433908 and GW433908/RTV When Administered to HIV-1 Infected Protease Inhibitor (PI) Naive and PI-experienced Pediatric Subjects Aged 4 Weeks to <2 Years.
INTERVENTIONAL
Inicio: 23 de oct de 2003
ID: NCT00071760
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
INTERVENTIONAL
Inicio: 9 de oct de 2024
ID: NCT06630286
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Observer-blind, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Dose Levels of Ad26.COV2.S Administered as a One- or Two-dose Regimen in Healthy Adolescents From 12 to 17 Years Inclusive
INTERVENTIONAL
Inicio: 27 de sept de 2021
ID: NCT05007080
Completado
Fase 4
ClinicalTrials.gov
A Single Arm, Open-label, Multicenter, Phase IV Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis
INTERVENTIONAL
Inicio: 1 de ene de 2012
ID: NCT01519661
Completado
Fase 2
ClinicalTrials.gov
A Phase IIb Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Two Doses of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Adults 18 Years of Age and Older, Living With HIV.
INTERVENTIONAL
Inicio: 24 de jun de 2021
ID: NCT05005156
Completado
ClinicalTrials.gov
Positive Connections: COPA2
INTERVENTIONAL
Inicio: 1 de jul de 2016
ID: NCT02846350
Completado
ClinicalTrials.gov
USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid Among Healthy People and Health Personnel
OBSERVATIONAL
Inicio: 1 de jun de 2020
ID: NCT04425850
Completado
Fase 1
ClinicalTrials.gov
A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Immunomodulatory Effect of the RIPK1 Inhibitor SAR443122 in Hospitalized Patients With Severe COVID-19
INTERVENTIONAL
Inicio: 17 de jul de 2020
ID: NCT04469621
Completado
Fase 3
ClinicalTrials.gov
An Evaluation of Bone Mineral Density in HIV-1-infected Adult Subjects Switching From a Tenofovir-containing Antiretroviral Therapy Regimen to a Dolutegravir Plus Rilpivirine Regimen
INTERVENTIONAL
Inicio: 12 de jun de 2015
ID: NCT02478632
Terminado
Fase 3
ClinicalTrials.gov
A Phase 2/3 Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Prevention of COVID-19 (EVADE)
INTERVENTIONAL
Inicio: 27 de abr de 2021
ID: NCT04859517
Completado
Fase 3
ClinicalTrials.gov
A Phase III Randomized, Double-blinded, Placebo-controlled Trial to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an ART Regimen, Including TMC114/RTV and an Investigator-selected OBR, in HIV-1 Infected Patients With Limited Treatment to no Treatment Options.
INTERVENTIONAL
Inicio: 1 de nov de 2005
ID: NCT00254046
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-blind Trial of TMC278 25 mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-naive HIV-1 Infected Subjects.
INTERVENTIONAL
Inicio: 1 de may de 2008
ID: NCT00540449
Terminado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
INTERVENTIONAL
Inicio: 13 de feb de 2017
ID: NCT03053050
Completado
Fase 3
ClinicalTrials.gov
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals
INTERVENTIONAL
Inicio: 31 de oct de 2019
ID: NCT03964415
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3b, Multi-center, Randomized, Parallel-group, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Oral Dolutegravir/Lamivudine Once-daily as a First-line Regimen Compared to Oral Bictegravir/Emtricitabine/Tenofovir Alafenamide Once Daily for Virologic Suppression and Maintenance in Antiretroviral Therapy Naive Adults Living With HIV
INTERVENTIONAL
Inicio: 9 de feb de 2024
ID: NCT05979311
Completado
Fase 2
ClinicalTrials.gov
An Open Label, Phase II Study of Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART
INTERVENTIONAL
Inicio: 1 de abr de 2001
ID: NCT00038532
Anterior
1
...
36
37
38
...
434
Siguiente
Filtros